Confirmatory Tests Sample Clauses

The Confirmatory Tests clause establishes the requirement for specific tests to be conducted to verify that goods or services meet agreed-upon standards or specifications. In practice, this clause outlines the procedures, timing, and criteria for such tests, often specifying who is responsible for conducting them and what happens if the goods or services fail to pass. Its core function is to ensure quality assurance and provide a clear mechanism for addressing non-conformance before final acceptance or payment.
Confirmatory Tests. A. If a drug screening test is positive, a confirmatory test shall be conducted utilizing a second sample of fluid from the same container collected in the manner prescribed above. B. In the event the second test confirms the results of the first test, the Employer may proceed with the sanctions as set forth in this Article. C. In the event that the second test contradicts the result of the first test, the employee shall be given the benefits of the doubt and no sanctions shall be imposed. D. In the event that both results are positive, the employee is entitled to have the sample in the second container tested in the manner as prescribed above. The results of these tests, whether positive or negative, shall be determinative.
View SourceView Similar (4)
Confirmatory Tests. 1. If a drug screening test is positive, a confirmatory test shall be conducted utilizing the fluid from no more than two of the three containers collected in the manner prescribed above. 2. In the event the second test confirms the results of the first test, the Employer may proceed with the sanctions as set forth in this Article. 3. In the event that the second test contradicts the result of the first test, the Employer may request a third test in accordance with the procedures prescribed above. The results of this test, if positive, shall allow the Employer to proceed with sanctions as set forth in this Article. If the results are negative, the employee shall be given the benefit of the doubt and no sanctions shall be imposed.
View SourceView Similar (4)
Confirmatory Tests. If a drug screening test is positive, a confirmatory test shall be conducted 10 utilizing the fluid from no more than two (2) of the three (3) containers 11 collected in the manner prescribed above.
View SourceView Similar (2)
Confirmatory Tests. 1. If a drug‐screening test is positive, a confirmatory test shall be conducted in the manner prescribed in the laboratory’s procedures. a. In the event the second test confirms the results of the first test, the City may proceed with appropriate discipline. b. In the event the second test contradicts the result of the first test, a third test will be completed in accordance with the procedures prescribed above. c. The results of the third test, if positive, shall allow the City to proceed with discipline as set forth in this policy. If the results of the third test are negative, discipline shall not be imposed.
View SourceView Similar (2)
Confirmatory Tests. A. If a drug screening test is positive, a confirmatory test shall be conducted in the manner prescribed in the laboratory’s procedures. B. In the event the second test confirms the results of the first test, the Employer may proceed with appropriate discipline. C. In the event that the second test contradicts the result of the first test, the Employer may request a third test in accordance with the procedures prescribed above. The Employer shall pay for the cost of this test. The results of this test, if positive, shall allow the Employer to proceed with discipline as set forth in this article. If the results of the third test are negative, discipline shall not be imposed.
View Source

Related to Confirmatory Tests

  • Laboratory Testing All laboratories selected by UPS Freight for analyzing Controlled Substances Testing will be HHS certified.

  • Commercialization Reports Throughout the term of this Agreement and during the Sell-Off Period, and within thirty (30) days of December 31st of each year, Company will deliver to University written reports of Company’s and Sublicensees’ efforts and plans to develop and commercialize the innovations covered by the Licensed Rights and to make and sell Licensed Products. Company will have no obligation to prepare commercialization reports in years where (a) Company delivers to University a written Sales Report with active sales, and (b) Company has fulfilled all Performance Milestones. In relation to each of the Performance Milestones each commercialization report will include sufficient information to demonstrate achievement of those Performance Milestones and will set out timeframes and plans for achieving those Performance Milestones which have not yet been met.

  • ODUF Packing Specifications 6.3.1 A pack will contain a minimum of one message record or a maximum of 99,999 message records plus a pack header record and a pack trailer record. One transmission can contain a maximum of 99 packs and a minimum of one pack.

  • Implementation Report Within 150 days after the Effective Date, Ensign Group shall submit a written report to OIG summarizing the status of its implementation of the requirements of this CIA (Implementation Report). The Implementation Report shall, at a minimum, include: 1. the name, address, phone number, and position description of the Compliance Officer required by Section III.A, and a summary of other noncompliance job responsibilities the Compliance Officer may have; 2. the names and positions of the members of the Compliance Committee required by Section III.A; 3. the names and positions of the members of the Board of Directors who are responsible for satisfying the Board of Directors compliance obligations described in Section III.A.3; 4. a copy of Ensign Group’s Code of Conduct required by Section III.B.1; 5. the number of individuals required to complete the Code of Conduct certification required by Section III.B.1, the percentage of individuals who have completed such certification, and an explanation of any exceptions (the documentation supporting this information shall be available to OIG upon request); 6. a summary of all Policies and Procedures required by Section III.B (copies of the Policies and Procedures shall be made available to OIG upon request); 7. the following information regarding each type of training required by Section III.C: a. a description of such training, including a summary of the topics covered, the length of sessions, and a schedule of training sessions; b. the number of individuals required to be trained, percentage of individuals actually trained, and an explanation of any exceptions. A copy of all training materials and the documentation supporting this information shall be made available to OIG upon request. 8. a description of the Disclosure Program required by Section III.E; 9. the following information regarding the IRO(s): (a) identity, address, and phone number; (b) a copy of the engagement letter; (c) information to demonstrate that the IRO has the qualifications outlined in Appendix A to this CIA; (d) a summary and description of any and all current and prior engagements and agreements between Ensign Group and the IRO; and (e) a certification from the IRO regarding its professional independence and objectivity with respect to Ensign Group; 10. a description of the process by which Ensign Group fulfills the requirements of Section III.F regarding Ineligible Persons; 11. a list of all of Ensign Group’s locations (including locations and mailing addresses); the corresponding name under which each location is doing business; the corresponding phone numbers and fax numbers; each location’s Medicare and state Medicaid program provider number and/or supplier number(s); and the name and address of each Medicare and state Medicaid program contractor to which Ensign Group currently submits claims; 12. a description of Ensign Group’s corporate structure, including identification of any parent and sister companies, subsidiaries, and their respective lines of business; and

  • Stability Testing Patheon will conduct stability testing on the Products in accordance with the protocols set out in the Specifications for the separate fees and during the time periods set out in Schedule C. Patheon will not make any changes to these testing protocols without prior written approval from Client. If a confirmed stability test failure occurs, Patheon will notify Client within [***], after which Patheon and Client will jointly determine the proceedings and methods to be undertaken to investigate the cause of the failure, including which party will bear the cost of the investigation. Patheon will not be liable for these costs unless it has failed to perform the Manufacturing Services in accordance with the Specifications and cGMPs. Patheon will give Client all stability test data and results at Client’s request.